Crit Care:重症监护患者呼气流量受限的患病率和危险因素

2019-12-08 xing.T MedSci原创

由此可见,EFL在ICU患者中很常见,并且与不良预后相关。在ICU住院的前三天内,患者发生EFL的主要决定因素是体液平衡是否良好。需要进一步的研究来评估限制性液体疗法是否可能与较低的EFL发生率相关。

呼气流量限制(EFL)的特点是对呼气驱动压力不敏感的呼气流量显著减少。EFL的存在会影响呼吸和心血管功能并损害小气道。它的发生已在多种疾病中得到证实,例如COPD、哮喘、肥胖、心力衰竭、ARDS和囊性纤维化。近日,危重病医学领域权威杂志Critical Care上发表了一篇研究文章,研究人员的目的是评估需要机械通气的急性呼吸衰竭患者EFL患病率,并确定与EFL存在相关的主要临床特征、危险因素和临床结局。

在这项前瞻性观察性研究中,预期的机械通气时间为72 h。在ICU入院后24h内对患者进行了至少72h的评估,包括呼吸力学,通过PEEP测试是否存在EFL,每日体液平衡并进行结局测量。

在121例患者中,有37例(31% )患者在入院时出现了EFL。流量受限患者的BMI较高,有肺或心脏病史,呼吸困难评分更差,内在呼气末正压升高,血流和其他抵抗力较高。在最初的72h机械通气过程中,另外21例(17%)患者发生了EFL。与没有EFL的患者(65.8μml/kg)相比,新发作的EFL患者第3天出现更多正向累积液体平衡(103.3μml/kg)。流量受限的患者需要更长的机械通气时间,更长的ICU住院时间和更高的ICU死亡率。

由此可见,EFL在ICU患者中很常见,并且与不良预后相关。在ICU住院的前三天内,患者发生EFL的主要决定因素是体液平衡是否良好。需要进一步的研究来评估限制性液体疗法是否可能与较低的EFL发生率相关。
 
原始出处:

Carlo Alberto Volta,et al.Expiratory flow limitation in intensive care: prevalence and risk factors.Critical Care.2019.https://ccforum.biomedcentral.com/articles/10.1186/s13054-019-2682-4

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2018154, encodeId=bd2820181543b, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Wed Jun 24 03:44:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250657, encodeId=4bd0125065e40, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Dec 10 03:44:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551169, encodeId=166e1551169b0, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Tue Dec 10 03:44:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376703, encodeId=5bbb3e6703c7, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Sun Dec 08 19:15:56 CST 2019, time=2019-12-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2018154, encodeId=bd2820181543b, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Wed Jun 24 03:44:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250657, encodeId=4bd0125065e40, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Dec 10 03:44:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551169, encodeId=166e1551169b0, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Tue Dec 10 03:44:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376703, encodeId=5bbb3e6703c7, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Sun Dec 08 19:15:56 CST 2019, time=2019-12-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2018154, encodeId=bd2820181543b, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Wed Jun 24 03:44:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250657, encodeId=4bd0125065e40, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Dec 10 03:44:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551169, encodeId=166e1551169b0, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Tue Dec 10 03:44:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376703, encodeId=5bbb3e6703c7, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Sun Dec 08 19:15:56 CST 2019, time=2019-12-08, status=1, ipAttribution=)]
    2019-12-10 bioon6
  4. [GetPortalCommentsPageByObjectIdResponse(id=2018154, encodeId=bd2820181543b, content=<a href='/topic/show?id=d0ca9596415' target=_blank style='color:#2F92EE;'>#重症监护患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95964, encryptionId=d0ca9596415, topicName=重症监护患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73a3403, createdName=weihongyv, createdTime=Wed Jun 24 03:44:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250657, encodeId=4bd0125065e40, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Tue Dec 10 03:44:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551169, encodeId=166e1551169b0, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Tue Dec 10 03:44:00 CST 2019, time=2019-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376703, encodeId=5bbb3e6703c7, content=学习了,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzTetibytbqFDmFITWHyBWbxU7S9MYibgPSqvu0sYteH0N6zXqbU0Kf3Mbdb7yWM1Kud3zPgYBibE2SZ/0, createdBy=da7696924, createdName=qingfengqishi5, createdTime=Sun Dec 08 19:15:56 CST 2019, time=2019-12-08, status=1, ipAttribution=)]
    2019-12-08 qingfengqishi5

    学习了,学习了

    0